Limits...
The role of somatostatin receptor scintigraphy on the diagnosis of desmoid tumors.

Friesenbichler J, Molcan A, Aigner R, Sadoghi P, Liegl-Atzwanger B, Maurer-Ertl W, Weger C, Leithner A - ISRN Oncol (2012)

Bottom Line: Background.On the other hand, the correlation between the results of somatostatin receptor scintigraphy and immunohistochemical investigations was poor (two out of seven cases).Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedic Surgery, Medical University of Graz, Auenbruggerplatz 5, 8036 Graz, Austria.

ABSTRACT
Background. Magnetic resonance imaging is considered as imaging modality of choice in diagnosis of desmoid tumors, though even this technique can lack the ability to distinguish aggressive fibromatosis from other benign or malignant soft tissue tumors. The aim of this study was to investigate if desmoid tumors would show an adequate tracer uptake in somatostatin receptor scintigraphy and moreover to correlate these results with immunohistochemical staining. Patients and Methods. Thirteen patients with desmoid tumors were examined with somatostatin receptor scintigraphy. Additionally, seven of these patients have been tested for the immunohistochemical expression of somatostatin receptor subtype 2A. The results of somatostatin receptor scintigraphy and the results of immunohistochemical staining (somatostatin receptor subtype 2A) were evaluated and correlated. Results. Somatostatin receptor scintigraphy revealed that eight of 13 affected patients (62%) showed an enhanced tracer uptake. On the other hand, the correlation between the results of somatostatin receptor scintigraphy and immunohistochemical investigations was poor (two out of seven cases). Conclusion. The current study demonstrated that desmoid tumors frequently express somatostatin receptor subtype 2, while immunohistochemical investigations did not correlate with these findings. This may likely be due to lack of standardization of this technique and also due to heterogeneous receptor distribution within the tumors.

No MeSH data available.


Related in: MedlinePlus

Positive correlation of 111In-DTPA-octreotide scintigraphy and somatostatin receptor 2A immunohistochemistry. (a) Results of SRS showing enhanced tracer uptake at the side of the desmoid tumour at the bottom of the foot and (b) moderate immunohistochemical staining for somatostatin receptor subtype 2A (magnification ×40).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3369531&req=5

fig1: Positive correlation of 111In-DTPA-octreotide scintigraphy and somatostatin receptor 2A immunohistochemistry. (a) Results of SRS showing enhanced tracer uptake at the side of the desmoid tumour at the bottom of the foot and (b) moderate immunohistochemical staining for somatostatin receptor subtype 2A (magnification ×40).

Mentions: Somatostatin receptor scintigraphy was performed either preoperatively or at suspicion of disease relapse, by using established radiopharmaceuticals, namely, either 111In-DTPA-octreotide or 99mTc-EDDA/HYNIC-TOC (Figure 1(a)). The tracers were prepared with commercially available kits using standard techniques as described by the producers. 111In-DTPA-octreotide was used as tracer until 2008. Planar and SPECT investigations of the tumour regions were performed 4 or 5 and 24 hours after application of the radioactive tracer. Since 2009 SRS has been performed with 99mTc-EDDA/HYNIC-TOC, due to cost effectiveness and a simplifying one-day protocol. The scintigraphic procedure includes 1 and 4 hours postinjection planar and SPECT images of the tumour regions. Tracer uptake was described as enhanced (+) or nonpathological (−).


The role of somatostatin receptor scintigraphy on the diagnosis of desmoid tumors.

Friesenbichler J, Molcan A, Aigner R, Sadoghi P, Liegl-Atzwanger B, Maurer-Ertl W, Weger C, Leithner A - ISRN Oncol (2012)

Positive correlation of 111In-DTPA-octreotide scintigraphy and somatostatin receptor 2A immunohistochemistry. (a) Results of SRS showing enhanced tracer uptake at the side of the desmoid tumour at the bottom of the foot and (b) moderate immunohistochemical staining for somatostatin receptor subtype 2A (magnification ×40).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3369531&req=5

fig1: Positive correlation of 111In-DTPA-octreotide scintigraphy and somatostatin receptor 2A immunohistochemistry. (a) Results of SRS showing enhanced tracer uptake at the side of the desmoid tumour at the bottom of the foot and (b) moderate immunohistochemical staining for somatostatin receptor subtype 2A (magnification ×40).
Mentions: Somatostatin receptor scintigraphy was performed either preoperatively or at suspicion of disease relapse, by using established radiopharmaceuticals, namely, either 111In-DTPA-octreotide or 99mTc-EDDA/HYNIC-TOC (Figure 1(a)). The tracers were prepared with commercially available kits using standard techniques as described by the producers. 111In-DTPA-octreotide was used as tracer until 2008. Planar and SPECT investigations of the tumour regions were performed 4 or 5 and 24 hours after application of the radioactive tracer. Since 2009 SRS has been performed with 99mTc-EDDA/HYNIC-TOC, due to cost effectiveness and a simplifying one-day protocol. The scintigraphic procedure includes 1 and 4 hours postinjection planar and SPECT images of the tumour regions. Tracer uptake was described as enhanced (+) or nonpathological (−).

Bottom Line: Background.On the other hand, the correlation between the results of somatostatin receptor scintigraphy and immunohistochemical investigations was poor (two out of seven cases).Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedic Surgery, Medical University of Graz, Auenbruggerplatz 5, 8036 Graz, Austria.

ABSTRACT
Background. Magnetic resonance imaging is considered as imaging modality of choice in diagnosis of desmoid tumors, though even this technique can lack the ability to distinguish aggressive fibromatosis from other benign or malignant soft tissue tumors. The aim of this study was to investigate if desmoid tumors would show an adequate tracer uptake in somatostatin receptor scintigraphy and moreover to correlate these results with immunohistochemical staining. Patients and Methods. Thirteen patients with desmoid tumors were examined with somatostatin receptor scintigraphy. Additionally, seven of these patients have been tested for the immunohistochemical expression of somatostatin receptor subtype 2A. The results of somatostatin receptor scintigraphy and the results of immunohistochemical staining (somatostatin receptor subtype 2A) were evaluated and correlated. Results. Somatostatin receptor scintigraphy revealed that eight of 13 affected patients (62%) showed an enhanced tracer uptake. On the other hand, the correlation between the results of somatostatin receptor scintigraphy and immunohistochemical investigations was poor (two out of seven cases). Conclusion. The current study demonstrated that desmoid tumors frequently express somatostatin receptor subtype 2, while immunohistochemical investigations did not correlate with these findings. This may likely be due to lack of standardization of this technique and also due to heterogeneous receptor distribution within the tumors.

No MeSH data available.


Related in: MedlinePlus